OmniAb, Inc. Common Stock (OABI) Stock Price

OABIStock
$4.59+170.00%52W
Market Cap$667.34M
P/E—
PEG Ratio—
Div yield—
Beta0.61

OABI Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)204.48%
Price vs S&P 500 (4W)1.54%
VGM Score56.97

OABI Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.13-$0.05+60.78%(+$0.08)
Q1 2026-$0.10-$0.06+37.93%(+$0.04)
Q4 2025-$0.09-$0.11-25.71%(-$0.02)
Q3 2025-$0.14-$0.14-2.94%(-$0.00)
Q2 2025-$0.15-$0.15+1.10%(+$0.00)

OABI Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.23
4.23
4.23
4.23

Industry Peers — R&D — Physical Sciences(17)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/E Ratio (Annual)ROE (TTM)Revenue Growth (5Y)Indicated Dividend Yield (Annual)Price
OABIOmniAb, Inc. Common Stock
FBA—-16.6%-4.3%—$4.59
IQVIQVIA Holdings Inc.DCA32.3x21.9%7.5%—$266.90
INCYIncyte Genomics IncCBB17.8x29.6%14.0%—$113.07
MEDPMedpace Holdings, Inc. Common StockFBB38.3x110.2%22.3%—$618.47
CRLCharles River Laboratories International, Inc.FDA—-7.7%6.5%—$300.15
ICLRIcon PlcCCB57.3x0.8%24.1%—$170.18
ABSIAbsci Corporation Common StockFFB—-59.2%-10.1%—$8.25
NRCNRC Health Common StockDDB38.4x48.5%0.6%1.2%$20.15
MXCTMaxCyte, Inc. Common StockCDB—-21.0%4.8%—$1.30
IBACIB Acquisition Corp. Common Stock—DC15.9x-3.7%——$10.86
ONMDOneMedNet Corp Class A Common StockDAD—-6.8%——$4.51

About OmniAb, Inc. Common Stock

OmniAb licenses antibody discovery technology to pharmaceutical and biotech companies and academic institutions. The platform uses engineered transgenic animals powered by proprietary Biological Intelligence to rapidly identify optimized antibody candidates for drug development. The company generates revenue through licensing agreements that accelerate its partners' therapeutic discovery efforts.